低度血清性卵巢癌中的HER2/neu表达:一个试点两中心回顾性研究
Alina Badlaeva1,2, Aleksandra Asaturova1,2, Aleksandra Rogozhina1
1National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov of the Ministry of Health of Russia, Moscow 117513, Russia.
人体表皮生长因子受体-2 (HER2/neu) 的过度表达在低度血清性卵巢癌 (LGSOC) 中罕见. 需要进一步的研究,以探索在罕见的HER2/neu变异病例中潜在的向治疗方法.
科学领域:
- 在瘤学瘤学.
- 妇科病理学 妇科病理学
- 分子诊断学 分子诊断学
背景情况:
- 低度血清性卵巢癌 (LGSOC) 是一种不常见的卵巢癌亚型.
- LGSOC对常规化疗反应不佳,需要新的治疗点.
- 人体表皮生长因子受体-2 (HER2/neu) 是其他癌症中已确定的治疗点.
研究的目的:
- 为了研究HER2/neu在LGSOC.中的免疫组织化学 (IHC) 表达.
- 确定HER2/neu过度表达的频率和LGSOC中的超低表型.
- 为了将HER2/neu状态与LGSOC患者的临床结果相关联.
主要方法:
- 对2017年至2024年间诊断的33例LGSOC病例进行了回顾性分析.
- 使用4B5抗体对HER2/neu进行免疫组织化学 (IHC) 染色.
- 基于ASCO/CAP乳腺癌指南的HER2/neu评分.
主要成果:
- 大多数患者 (82.7%) 呈现了晚期LGSOC.
- 没有检测到HER2/neu过度表达;只有3.0%显示1+染色,6.1%显示超低表型.
- 临床随访数据表明结果各异,一些HER2-阴性和超低病例显示疾病进展或缓解.
结论:
- 在LGSOC中,HER2/neu过度表达异常罕见.
- 超低HER2/neu表型可能发生在LGSOC的一小部分.
- 对HER2/neu变化的进一步调查是有必要的,以确定潜在的向治疗候选人.
更多相关视频
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
08:26Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling
Published on: August 6, 2025
相关概念视频
Pilot and Numeric Relaying
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Types of Aggregate Grading
Well-graded aggregates include a complete range of necessary size fractions that fit together to create a dense matrix with minimal voids, represented by a smooth, continuous gradation curve. This type of grading ensures good...
